Search and Find the CMO / CDMO You Need for Your Project
Find the expertise you need for your drug development and manufacturing project
BIOLOGICS manufacturing site
MAI network supplier
Mabion is a European biologics development and manufacturing partner focused on biosimilar, large molecule manufacturing, and innovation programs.
Location available after registration
OLIGONUCLEOTIDES manufacturing site
MAI network supplier
Polpharma API is a European CDMO offering small-molecule, oligonucleotide, and payload-linker for ADC development and manufacturing
Location available after registration
BIOLOGICS manufacturing site
MAI network supplier
mRNA & LNP manufacturing and Fill and Finish.
Location available after registration
These facilities match your main criteria but not every optional filter — including other countries in the same region.
HISTOCELL S.L. | Cell Therapy, Exosomes & Secretomes
HISTOCELL
Histocell is a Spanish CDMO that develops and manufactures cell therapies, secretomes and exosomes, as well medical devices.
SERVICES: Development services, Analytical / QC services, Quality Assurance services, Manufacturing services
MARKETS: EMA (EU), PMDA (Japan), NMPA (China), FDA (USA), Health Canada (Canada), ANVISA (Brazil), ISP (Chile), MSPAS (Guatemala), COFEPRIS (Mexico), DIGEMID (Peru), Russian Health Authorities, MHRA (UK), ANMAT (Argentina), INVIMA (Colombia), MFDS (South Korea), CDSCO (India), TGA (Australia)
COMPLIANCE: ISO, EMA (EU GMP)
BSL (Biological Safety Level): 1, 2
CATEGORY / PRODUCT: COSMETICS, FDF / DRUG PRODUCTS, SERVICES, BIOLOGICS
USE: Human, Veterinary
THERAPEUTIC AREAS OF EXPERTISE (ATC): (N) Nervous system, (D) Dermatologicals, (B) Blood and blood forming organs, (R) Respiratory system, (M) Musculoskeletal system, (C) Cardiovascular system, (A) Digestive tract and metabolism
BATCH SIZE: Small, Medium
REGION: Europe
CARBOGEN AMCIS | Vionnaz
CARBOGEN AMCIS
Highly Potent APIs development and small-scale cGMP production including chromatography and lyophilization.
SERVICES: Development services, Analytical / QC services, Quality Assurance services, Manufacturing services
MARKETS: EMA (EU), PMDA (Japan), NMPA (China), FDA (USA), Health Canada (Canada), ANVISA (Brazil), MHRA (UK), MFDS (South Korea), CDSCO (India), TGA (Australia)
COMPLIANCE: FDA (cGMP), ISO, PMDA/MHLW (Japan GMP), ANVISA (Brazil B-GMP), EMA (EU GMP), World Health Organization (GMP / HACCP)
USE: Human, Veterinary
BATCH SIZE: Small
OEB (Occupational Exposure Banding): 3 (PDE = 100 - 1,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day), 4 / HPAPI (PDE = 10 - 100 µg/day), 2 (PDE = 1,000 - 10,000 µg/day)
REGION: Europe
CATEGORY / PRODUCT: CHEMICAL-SYNTHETIC
SERVICES: Development services, Logistics, Analytical / QC services, Packaging, Regulatory services, Quality Assurance services, Manufacturing services
MARKETS: EMA (EU), PMDA (Japan), NMPA (China), FDA (USA), Health Canada (Canada), ANVISA (Brazil), ISP (Chile), MSPAS (Guatemala), COFEPRIS (Mexico), DIGEMID (Peru), Russian Health Authorities, MHRA (UK), ANMAT (Argentina), INVIMA (Colombia), MFDS (South Korea), EDE (UAE), TGA (Australia)
COMPLIANCE: DIGEMID, FDA (cGMP), ISO, PMDA/MHLW (Japan GMP), ANVISA (Brazil B-GMP), MSPAS, COFEPRIS, Roszdravnadzor (Russia GMP), ECOVADIS, TGA (Australia GMP), INVIMA, ISP (Chile BPM), French Service-Public (CIR), NMPA (China GMP), ANMAT (Argentina nueva GMP), EMA (EU GMP), Health Canada (Canada GMP), World Health Organization (GMP / HACCP), MHRA (UK GMP), MFDS/KFDA (Republic of Korea GMP)
USE: Human
BATCH SIZE: Large, Small, Medium
THERAPEUTIC AREAS OF EXPERTISE (ATC): (N) Nervous system, (J) Antiinfectives for systemic use, (D) Dermatologicals, (R) Respiratory system, (M) Musculoskeletal system, (G) Genito urinary system and sex hormones, (C) Cardiovascular system, (A) Digestive tract and metabolism
CATEGORY / PRODUCT: FDF / DRUG PRODUCTS
OEB (Occupational Exposure Banding): 1 / low-hazard (PDE > 10,000 µg/day)
REGION: Europe
Laboratorios Grifols | Murcia Plant
Grifols International
Sterile manufacturing solutions (small molecules) in flexible bags.
MARKETS: EMA (EU), FDA (USA), ANVISA (Brazil), ANMAT (Argentina), MFDS (South Korea), TGA (Australia)
COMPLIANCE: FDA (cGMP), ISO, ANVISA (Brazil B-GMP), ECOVADIS, TGA (Australia GMP), INVIMA, ISP (Chile BPM), ANMAT (Argentina nueva GMP), EMA (EU GMP), Health Canada (Canada GMP), World Health Organization (GMP / HACCP), MHRA (UK GMP), MFDS/KFDA (Republic of Korea GMP)
USE: Human, Veterinary
BATCH SIZE: Large, Small, Medium
SERVICES: Logistics, Analytical / QC services, Packaging, Quality Assurance services, Manufacturing services
CONTROLLED SUBSTANCES: Lowest potential for abuse, Lower potential for abuse, Low potential for abuse
THERAPEUTIC AREAS OF EXPERTISE (ATC): (N) Nervous system, (J) Antiinfectives for systemic use, (M) Musculoskeletal system, (C) Cardiovascular system, (A) Digestive tract and metabolism
OEB (Occupational Exposure Banding): 3 (PDE = 100 - 1,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day), 2 (PDE = 1,000 - 10,000 µg/day)
CATEGORY / PRODUCT: FDF / DRUG PRODUCTS
REGION: Europe
Cenexi
Cenexi
GMP plant on a four-hectare site is located 9 km east of Paris. It is a center of excellence for injectable ampoules.
SERVICES: Development services, Logistics, Analytical / QC services, Packaging, Regulatory services, Quality Assurance services, Manufacturing services
MARKETS: EMA (EU), PMDA (Japan), NMPA (China), FDA (USA), Health Canada (Canada), ANVISA (Brazil), MHRA (UK), MFDS (South Korea), EDE (UAE), TGA (Australia)
COMPLIANCE: FDA (cGMP), PMDA/MHLW (Japan GMP), ANVISA (Brazil B-GMP), NMPA (China GMP), EMA (EU GMP), MFDS/KFDA (Republic of Korea GMP)
USE: Human, Veterinary
BATCH SIZE: Large, Small, Medium
CONTROLLED SUBSTANCES: Lowest potential for abuse, Lower potential for abuse, High potential for abuse & no medical use, High potential for abuse & medical use, Low potential for abuse
THERAPEUTIC AREAS OF EXPERTISE (ATC): (N) Nervous system, (J) Antiinfectives for systemic use, (D) Dermatologicals, (P) Antiparasitic products, insecticides and repellents, (M) Musculoskeletal system, (L) Antineoplastic and immunomodulating agents, (C) Cardiovascular system, (A) Digestive tract and metabolism
CATEGORY / PRODUCT: FDF / DRUG PRODUCTS
OEB (Occupational Exposure Banding): 1 / low-hazard (PDE > 10,000 µg/day)
REGION: Europe
Nexora Cell and Tissue Therapy Manufacturing Site
Green Phoenix Labs GmbH
Licensed ATMP site in Germany. GMP manufacturing and QP batch release for cell and tissue therapies.
SERVICES: Development services, Analytical / QC services, Packaging, Regulatory services, Quality Assurance services, Manufacturing services
MARKETS: EMA (EU)
BSL (Biological Safety Level): 1, 2
USE: Human
CONTROLLED SUBSTANCES: Lowest potential for abuse, Lower potential for abuse, Low potential for abuse
THERAPEUTIC AREAS OF EXPERTISE (ATC): (S) Sensory organs, (N) Nervous system, (D) Dermatologicals, (B) Blood and blood forming organs, (R) Respiratory system, (M) Musculoskeletal system, (G) Genito urinary system and sex hormones, (C) Cardiovascular system, (A) Digestive tract and metabolism
BATCH SIZE: Small, Medium
OEB (Occupational Exposure Banding): 3 (PDE = 100 - 1,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day), 2 (PDE = 1,000 - 10,000 µg/day)
COMPLIANCE: EMA (EU GMP)
CATEGORY / PRODUCT: FDF / DRUG PRODUCTS, SERVICES, BIOLOGICS
REGION: Europe
CARBOGEN AMCIS | Bubendorf
CARBOGEN AMCIS
Development and cGMPmanufacturing of Highly Potent API including Antibody Drug Conjugates (ADC).
SERVICES: Development services, Analytical / QC services, Regulatory services, Quality Assurance services, Manufacturing services
MARKETS: EMA (EU), PMDA (Japan), NMPA (China), FDA (USA), Health Canada (Canada), ANVISA (Brazil), ISP (Chile), MSPAS (Guatemala), COFEPRIS (Mexico), DIGEMID (Peru), MHRA (UK), ANMAT (Argentina), INVIMA (Colombia), MFDS (South Korea), Turkish Health Authorities, CDSCO (India), TGA (Australia)
COMPLIANCE: FDA (cGMP), ISO, PMDA/MHLW (Japan GMP), ANVISA (Brazil B-GMP), EMA (EU GMP), World Health Organization (GMP / HACCP)
USE: Human, Veterinary
THERAPEUTIC AREAS OF EXPERTISE (ATC): (V09-10) Radiopharmaceuticals, (N) Nervous system, (D) Dermatologicals, (B) Blood and blood forming organs, (R) Respiratory system, (M) Musculoskeletal system, (L) Antineoplastic and immunomodulating agents, (C) Cardiovascular system, (A) Digestive tract and metabolism
BATCH SIZE: Small, Medium
OEB (Occupational Exposure Banding): 3 (PDE = 100 - 1,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day), 4 / HPAPI (PDE = 10 - 100 µg/day), 2 (PDE = 1,000 - 10,000 µg/day)
CATEGORY / PRODUCT: PARTICLE ENGINEERING, SERVICES, BIOLOGICS, CHEMICAL-SYNTHETIC
REGION: Europe
HIPRA BIOTECH SERVICES | Amer
HIPRA Biotech Services
End-to-end internal capabilities from cell line development to commercial manufacturing.
SERVICES: Development services, Logistics, Analytical / QC services, Packaging, Regulatory services, Quality Assurance services, Manufacturing services
MARKETS: EMA (EU), PMDA (Japan), FDA (USA), Health Canada (Canada), ANVISA (Brazil), ISP (Chile), MSPAS (Guatemala), COFEPRIS (Mexico), DIGEMID (Peru), MHRA (UK), ANMAT (Argentina), INVIMA (Colombia)
COMPLIANCE: DIGEMID, FDA (cGMP), ISO, PMDA/MHLW (Japan GMP), ANVISA (Brazil B-GMP), MSPAS, COFEPRIS, INVIMA, ISP (Chile BPM), ANMAT (Argentina nueva GMP), EMA (EU GMP), Health Canada (Canada GMP), World Health Organization (GMP / HACCP), MHRA (UK GMP)
BSL (Biological Safety Level): 1, 2
USE: Human, Veterinary
BATCH SIZE: Large, Small, Medium
OEB (Occupational Exposure Banding): 3 (PDE = 100 - 1,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day), 2 (PDE = 1,000 - 10,000 µg/day)
CATEGORY / PRODUCT: FDF / DRUG PRODUCTS, BIOLOGICS
REGION: Europe
JAFRAL
JAFRAL
Integrated biotechnology facility providing R&D, non-GMP and GMP manufacturing, QC testing, and fill & finish services for advanced biologics.
SERVICES: Development services, Logistics, Analytical / QC services, Packaging, Regulatory services, Quality Assurance services, Manufacturing services
COMPLIANCE: ICH, FDA (cGMP), ISO, EMA (EU GMP), World Health Organization (GMP / HACCP), SQF (Safe Quality Food)
MARKETS: EMA (EU), PMDA (Japan), FDA (USA), Health Canada (Canada), ANVISA (Brazil), MHRA (UK), SFDA (Saudi Arabia), Turkish Health Authorities, EDE (UAE), CDSCO (India), TGA (Australia)
BSL (Biological Safety Level): 1, 2
CATEGORY / PRODUCT: COSMETICS, NUTRACEUTICALS, FDF / DRUG PRODUCTS, SERVICES, BIOLOGICS
USE: Human, Veterinary
BATCH SIZE: Large, Small, Medium
CONTROLLED SUBSTANCES: Lowest potential for abuse
THERAPEUTIC AREAS OF EXPERTISE (ATC): (J) Antiinfectives for systemic use, (D) Dermatologicals, (V06) Nutrients, (R) Respiratory system, (A) Digestive tract and metabolism
REGION: Europe
Are you a pharmaceutical company seeking a reliable CMO or CDMO partner to accelerate your drug development process? Look no further than MAI CDMO Network. Our advanced search platform connects you with a vast network of qualified contract manufacturers and development organizations worldwide.
Why Choose MAI CDMO Network?
- Comprehensive Provider Directory: Discover a diverse range of CMOs and CDMOs specializing in various services, including API manufacturing, clinical trial supplies, fill-finish, packaging, and more.
- Tailored Search Capabilities: Our advanced search filters allow you to refine your search based on specific criteria such as location, capabilities, capacity, and regulatory compliance.
- Global Reach: Connect with CMOs and CDMOs from around the world to find the perfect partner for your global projects.
- Time and Cost Savings: Streamline your sourcing process and reduce time-to-market by finding the right partner on our platform.
- Enhanced Decision Making: Access detailed company profiles, case studies, and reviews to make informed decisions.
How MAI CDMO Network Works
- Create a Free Account: Sign up for a free account to access our extensive database of CMOs and CDMOs.
- Refine Your Search: Use our advanced search filters to identify providers that meet your exact requirements.
- Request Quotes: Contact selected providers directly to request quotes and learn more about their services.
- Make Informed Decisions: Compare quotes, review company profiles, and select the best partner for your project.
Key Benefits of Partnering with a CMO/CDMO
- Accelerated Time-to-Market: Leverage the expertise and resources of a CMO/CDMO to expedite your drug development process.
- Reduced Costs: Benefit from economies of scale and specialized equipment to reduce manufacturing costs.
- Improved Quality: Ensure product quality and compliance with regulatory standards through rigorous quality management systems.
- Increased Flexibility: Scale up or down production as needed to meet changing market demands.
- Focus on Core Competencies: Outsource non-core activities to free up internal resources for innovation and strategic initiatives.
Featured Services
- API Manufacturing: Source high-quality active pharmaceutical ingredients from experienced manufacturers.
- Clinical Trial Supplies: Secure reliable and compliant supplies for your clinical trials.
- Fill-Finish and Packaging: Partner with experts in sterile filling, lyophilization, and packaging to ensure product stability and patient safety.
- Analytical Testing: Access a wide range of analytical services to support your drug development program.
Ready to Find Your Ideal CMO/CDMO Partner? Register Now
Explore our platform today and discover how MAI CDMO Network can help you achieve your drug development goals.